Immune infiltrates in breast cancer: recent updates and clinical implications

MV Dieci, F Miglietta, V Guarneri - Cells, 2021 - mdpi.com
In recent decades, the increasing interest in the field of immunotherapy has fostered an
intense investigation of the breast cancer (BC) immune microenvironment. In this context …

Clinical implications of the intrinsic molecular subtypes of breast cancer

A Prat, E Pineda, B Adamo, P Galván, A Fernández… - The Breast, 2015 - Elsevier
Gene-expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer …

[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …

AS Coates, EP Winer, A Goldhirsch, RD Gelber… - Annals of oncology, 2015 - Elsevier
ABSTRACT The 14th St Gallen International Breast Cancer Conference (2015) reviewed
substantial new evidence on locoregional and systemic therapies for early breast cancer …

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

B Wallden, J Storhoff, T Nielsen, N Dowidar… - BMC medical …, 2015 - Springer
Background The four intrinsic subtypes of breast cancer, defined by differential expression of
50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of …

Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients

TZ Tan, QH Miow, Y Miki, T Noda, S Mori… - EMBO molecular …, 2014 - embopress.org
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized
to be co‐opted by carcinoma during invasion and metastasis. Yet, there is still no …

Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)–positive breast cancer

N Braman, P Prasanna, J Whitney, S Singh… - JAMA network …, 2019 - jamanetwork.com
Importance There has been significant recent interest in understanding the utility of
quantitative imaging to delineate breast cancer intrinsic biological factors and therapeutic …

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive …

A Llombart-Cussac, J Cortés, L Paré, P Galván… - The lancet …, 2017 - thelancet.com
Background HER2-positive breast cancer consists of four intrinsic molecular subtypes—
luminal A, luminal B, HER2-enriched, and basal-like—and a normal-like subtype, with the …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - The Lancet …, 2014 - thelancet.com
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Tumor-derived cell lines as molecular models of cancer pharmacogenomics

A Goodspeed, LM Heiser, JW Gray… - Molecular Cancer …, 2016 - AACR
Compared with normal cells, tumor cells have undergone an array of genetic and epigenetic
alterations. Often, these changes underlie cancer development, progression, and drug …

Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

JM Cejalvo, E Martínez de Dueñas, P Galván… - Cancer research, 2017 - AACR
Biological changes that occur during metastatic progression of breast cancer are still
incompletely characterized. In this study, we compared intrinsic molecular subtypes and …